This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-19 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The first SPR immunoassay was proposed in 1983 by Liedberg, Nylander, and Lundström, then of the Linköping Institute of Technology (Sweden). They adsorbed human IgG onto a 600-Ångström silver film, and used the assay to detect anti-human IgG in water solution. Unlike many other immunoassays, such as ELISA, an SPR immunoassay is label free in that a label molecule is not required for detection of the analyte. Additionally, the measurements on SPR can be followed real-time allowing the monitoring of individual steps in sequential binding events particularly useful in the assessment of for instance sandwich complexes.
=== Historical sites === Lebanon is the home of the Historic Cragun House. Built in 1893, it was once the home of Strange Nathaniel Cragun and his family. The family travelled the world, and their house is now a living history museum full of the pieces they collected from their travels as well as original furniture from the dwelling. This Victorian home is owned and maintained by the Boone County Historical Society and serves as headquarters for the organization. The Cragun House has been added to the National Register of Historic Places. Also listed on the National Register of Historic Places are the Boone County Courthouse and Oak Hill Cemetery.
The number of bones varies between individuals and with age – newborn babies have over 270 bones some of which fuse together. These bones are organized into a longitudinal axis, the axial skeleton, to which the appendicular skeleton is attached. The human skeleton takes 20 years before it is fully developed, and the bones contain marrow, which produces blood cells. There exist several general differences between the male and female skeletons. The male skeleton, for example, is generally larger and heavier than the female skeleton. In the female skeleton, the bones of the skull are generally less angular. The female skeleton also has wider and shorter breastbone and slimmer wrists. There exist significant differences between the male and female pelvis which are related to the female's pregnancy and childbirth capabilities. The female pelvis is wider and shallower than the male pelvis. Female pelvises also have an enlarged pelvic outlet and a wider and more circular pelvic inlet. The angle between the pubic bones is known to be sharper in males, which results in a more circular, narrower, and near heart-shaped pelvis.
=== Ethics === In April 2026, Pritzker signed an executive order barring state employees from betting on prediction markets like Kalshi or Polymarket while aided by nonpublic information acquired from their jobs.
=== Operation Epic Fury, 2026 === It was announced on 24 March 2026 that the Pentagon had ordered the commander of the 82nd Airborne Division, Major General Brandon R. Tegtmeier, and his headquarters staff to the Middle East, ahead of a potential deployment of a brigade combat team of around 3,000 troops to support operations against Iran. The U.S. Army extended the 82nd Airborne Division’s deployment to the Middle East to a full year, due to “operational requirements”. The extended deployment was announced by Major General Tegtmeier in a letter to military families.
Sources: en.wikipedia.org
The pulmonary trunk divides into pulmonary arteries and progressively smaller arteries throughout the lungs, until it reaches capillaries. As these pass by alveoli carbon dioxide is exchanged for oxygen. This happens through the passive process of diffusion. In the left heart, oxygenated blood is returned to the left atrium via the pulmonary veins. It is then pumped into the left ventricle through the mitral valve and into the aorta through the aortic valve for systemic circulation. The aorta is a large artery that branches into many smaller arteries, arterioles, and ultimately capillaries. In the capillaries, oxygen and nutrients from blood are supplied to body cells for metabolism, and exchanged for carbon dioxide and waste products. Capillary blood, now deoxygenated, travels into venules and veins that ultimately collect in the superior and inferior vena cavae, and into the right heart.
Cardiac markers are biomarkers measured to evaluate heart function. They can be useful in the early prediction or diagnosis of disease. Although they are often discussed in the context of myocardial infarction, other conditions can lead to an elevation in cardiac marker level. Cardiac markers are used for the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome and for management and prognosis in patients with diseases like acute heart failure. Most of the early markers identified were enzymes, and as a result, the term "cardiac enzymes" is sometimes used. However, not all of the markers currently used are enzymes. For example, in formal usage, troponin would not be listed as a cardiac enzyme.
Theft of prisoner's possessions by soldiers, dirty, cramped quarters and bad food, prisoners forced into uncomfortable positions for prolonged periods of time, extreme exposure to the elements, and excessive jailings of people based on the paid testimony of individual informants were reported. 55-year-old cafe owner Mahmoud Khodair, who was arrested and held for six months before being released in early March without ever knowing what he was charged with, stated, "It was just like hell", and "Nothing has changed since Saddam. Before, the Mukhabarat [secret police] would take us away, and at least they wouldn't blow down the door. Now, some informant fingers you and gets $100 even if you're innocent." During April 2004 the media started to report on the abuse. The journalist Seymour Hersh (who was awarded the Pulitzer Prize for his disclosure of the Vietnam War tragedy at the hamlet of My Lai) published a series of articles in The New Yorker with photo coverage of U.S. soldiers abusing prisoners in the Abu Ghraib prison on 2004-04-30. In an interview with Dan Rather, the deputy director of operations for the US-led coalition, Brig. Gen. Mark Kimmitt, stated "We're appalled. These are our fellow soldiers. These are the people we work with every day. They represent us. They wear the same uniform as us, and they let their fellow soldiers down.
=== Terrestrial plants in aquatic environments === Terrestrial plants may undergo physiological changes when submerged due to flooding. When submerged, new leaf growth has been found to have thinner leaves and thinner cell walls than the leaves on the plant that grew while above water, along with oxygen levels being higher in the portion of the plant grown underwater versus the sections that grew in their terrestrial environment. This is considered a form of phenotypic plasticity as the plant, once submerged, experiences changes in morphology better suited to their new aquatic environment. However, while some terrestrial plants may be able to adapt in the short-term to an aquatic habitat, it may not be possible to reproduce underwater, especially if the plant usually relies on terrestrial pollinators.
cell membrane Also plasma membrane, cytoplasmic membrane, and plasmalemma. The selectively permeable membrane surrounding all prokaryotic and eukaryotic cells, defining the outermost boundary of the cell and physically separating the cytoplasm from the extracellular environment. Like all membranes, the cell membrane is a flexible, fluid, sheet-like phospholipid bilayer with membrane proteins, carbohydrates, and numerous other molecules embedded within or interacting with it from both sides. Embedded molecules often have freedom to move laterally alongside the membrane's lipids. Though the cell membrane can be freely crossed by many ions, small organic molecules, and water, most other substances require active transport through special pores or channels or by endocytosis or exocytosis in order to enter or exit the cell, especially very large or electrically charged molecules such as proteins and nucleic acids. Besides regulating the transport of substances into and out of the cell, the cell membrane creates an organized interior space in which to perform life-sustaining activities and plays fundamental roles in all of the cell's interactions with its environment, making it important in cell signaling, motility, defense, and division, among numerous other processes.
Sources: en.wikipedia.org
In 1976, economist Rudolf Meidner established a study committee that came up with a proposal called the Meidner Plan which entailed the transferring of the excess profits into investment funds controlled by the workers in said efficient firms, with the goal that firms would create further employment and pay workers higher wages in return rather than unduly increasing the wealth of company owners and managers. Capitalists immediately denounced the proposal as socialism and launched an unprecedented opposition and smear campaign against it, threatening to terminate the class compromise established in the 1938 Saltsjöbaden Agreement.
autonomy – the patient has the right to refuse or choose their treatment. (Latin: Voluntas aegroti suprema lex.) beneficence – a practitioner should act in the best interest of the patient. (Latin: Salus aegroti suprema lex.) justice – concerns the distribution of scarce health resources, and the decision of who gets what treatment (fairness and equality). non-maleficence – "first, do no harm" (Latin: primum non-nocere). respect for persons – the patient (and the person treating the patient) have the right to be treated with dignity. truthfulness and honesty – the concept of informed consent has increased in importance since the historical events of the Doctors' Trial of the Nuremberg trials, Tuskegee syphilis experiment, and others. Such values do not give answers as to how to handle a particular situation, but provide a useful framework for understanding conflicts. When moral values are in conflict, the result may be an ethical dilemma or crisis. Sometimes, no good solution to a dilemma in medical ethics exists, and occasionally, the values of the medical community (i.e., the hospital and its staff) conflict with the values of the individual patient, family, or larger non-medical community. Conflicts can also arise between health care providers or among family members. For example, some argue that the principles of autonomy and beneficence clash when patients refuse blood transfusions, considering them life-saving; and truth-telling was not emphasized to a large extent before the HIV era.
== Pharmacology == Nordazepam is a partial agonist at the GABAA receptor, which makes it less potent than other benzodiazepines, particularly in its amnesic and muscle-relaxing effects. Its elimination half-life is between 36 and 200 hours, with wide variation among individuals; factors such as age and sex are known to impact it. The variation of reported half-lives are attributed to differences in nordazepam metabolism and that of its metabolites as nordazepam is hydroxylated to active metabolites such as oxazepam, before finally being glucuronidated and excreted in the urine. This can be attributed to extremely variable hepatic and renal metabolic functions among individuals depending upon a number of factors (including age, ethnicity, disease, and current or previous use/abuse of other drugs/medicines).
== Carbamino compounds in blood == The concentration of carbamate (HbCO2) was estimated in oxygenated and deoxygenated red blood cells of adult and fetal humans. The estimation was carried out at a constant pressure of carbon dioxide (PCO2 = 40 mm Hg) and varied pH levels of the serum. The bicarbonate concentration in the red cells was calculated using the Donnan ratio for chloride and bicarbonate ions. Based on this figure, the carbamate concentration was determined by subtracting the bicarbonate concentration and dissolved CO2 from the total CO2 concentration. Deoxygenated fetal red cells contain more HbCO2 than deoxygenated adult red cells at a given pH value in the red cell. Upon oxygenation, HbCO2 decreased in both types of erythrocytes to values lower than in deoxygenated cells, at a constant pH. The fraction of 'oxylabile carbamate' (-ΔHbCO2/ΔHbO2) at a red cell pH of 7·2 and a PCO2 of 40 mm Hg is 0·117 in fetal and 0·081 in adult erythrocytes. The apparent carbamate equilibrium constants (K'c and K'z) were calculated from the fraction of moles carbamate formed per Hb monomer (moles CO2/mole Hbi). These constants can be used to estimate the carbamate concentration in normal adult and fetal blood. In adult red cells, the first apparent dissociation constant of carbonic acid is significantly higher in oxygenated (-log10K'1 = pK'1 = 6·10) than in deoxygenated (pK'1 = 6·12) red cells, whereas in fetal red cells, the difference is smaller and statistically not significant.
People with MASLD often have no noticeable symptoms, and it is often only detected during routine blood tests or unrelated abdominal imaging or liver biopsy. In some cases, it can cause symptoms related to liver dysfunction such as fatigue, malaise, and dull right-upper-quadrant abdominal discomfort. Mild yellow discoloration of the skin may occur, although this is rare. MASH can severely impair liver function, leading to cirrhosis, liver failure, and liver cancer.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.